The results of two randomized, double blind, placebo studies found<unk>  treatment could benefit patients suffering from colds due to picornaviruses. Participants in the studies were healthy adults from Canada and the United States, with self-diagnosed colds that had occurred within 24 hours of trial enrollment. Participants were randomly given a placebo or two 200 mg tablets to take three times daily for five days. To increase absorption it was recommended to be taken after a meal. To monitor the effectiveness of<unk> , participants recorded the severity of their symptoms and nasal mucosal samples were obtained at enrollment, day 3, day 6 and day 18. The two studies had a total of 2096 participants and more than 90% (1945) completed the trial. The most common reason for a participant not finishing the trial was an adverse event.<unk>  treatment showed a reduction in nose blowing, sleep disturbance, and less cold medication used. Another study showed over 87% of virus isolates in cell culture were inhibited by<unk> . Virus variants were detected in 0.7% of the placebo group and 10.7% of the<unk>  group. Of the two isolates a subject from the placebo group had a resistant virus in cell culture to<unk> . The other strain was susceptible to the drug. The<unk>  group had 21 virus strains, which remained susceptible. Resistance strains were found in 7<unk>  patients. A Phase II study that used an intranasal formulation of<unk>  failed to show a statistically significant result for either of its two primary efficacy endpoints, percentage of participants with rhinovirus PCR-positive colds and percentage of participants with asthma exacerbations together with rhinovirus-positive PCR.
Pleconaril
Mitapivat
Enarodustat
Proxicromil
Lemborexant
Riociguat
Plerixafor
Avacopan